Iron reduction response and demographic differences between diabetics and non-diabetics with cardiovascular disease entered to a controlled clinical trial by Zacharski, Leo et al.
Dartmouth College
Dartmouth Digital Commons
Open Dartmouth: Faculty Open Access Articles
12-11-2017
Iron reduction response and demographic
differences between diabetics and non-diabetics





Department of Veteran Affairs
Bruce Chow
Department of Veteran Affairs
Follow this and additional works at: https://digitalcommons.dartmouth.edu/facoa
Part of the Cardiovascular Diseases Commons, and the Endocrinology, Diabetes, and
Metabolism Commons
This Article is brought to you for free and open access by Dartmouth Digital Commons. It has been accepted for inclusion in Open Dartmouth: Faculty
Open Access Articles by an authorized administrator of Dartmouth Digital Commons. For more information, please contact
dartmouthdigitalcommons@groups.dartmouth.edu.
Recommended Citation
Zacharski, Leo; Shamayeva, Galina; and Chow, Bruce, "Iron reduction response and demographic differences between diabetics and
non-diabetics with cardiovascular disease entered to a controlled clinical trial" (2017). Open Dartmouth: Faculty Open Access Articles.
422.
https://digitalcommons.dartmouth.edu/facoa/422
This is an Accepted Manuscript, which has been through the  
Royal Society of Chemistry peer review process and has been 
accepted for publication.
Accepted Manuscripts are published online shortly after 
acceptance, before technical editing, formatting and proof reading. 
Using this free service, authors can make their results available 
to the community, in citable form, before we publish the edited 
article. We will replace this Accepted Manuscript with the edited 
and formatted Advance Article as soon as it is available.
You can find more information about Accepted Manuscripts in the 
author guidelines.
Please note that technical editing may introduce minor changes 
to the text and/or graphics, which may alter content. The journal’s 
standard Terms & Conditions and the ethical guidelines, outlined 
in our author and reviewer resource centre, still apply. In no 
event shall the Royal Society of Chemistry be held responsible 
for any errors or omissions in this Accepted Manuscript or any 







David P. Giedroc et al.
The S2 Cu(I) site in CupA from Streptococcus pneumoniae is required for 
cellular copper resistance















This article can be cited before page numbers have been issued, to do this please use:  L. Zacharski, G.
Shamayeva and B. K. Chow, Metallomics, 2017, DOI: 10.1039/C7MT00282C.
Significance to Metallomics (100 words)  
 
Damaging effects of redox-active iron are implicated in the pathogenesis of common diseases 
including cardiovascular disease and diabetes. Adverse effects of iron in physiologic excess 
contributory to macro- and micro-vascular disease, insulin resistance, autophagy, the anemia of 
chronic disease and pancreatic beta cell injury may be evaluated in clinical trials aimed at 
“normalizing” body iron status for disease prevention and treatment. Characterization of 
disease manifestations and intermediate effects of intervention on iron status in diabetics and 
non-diabetics documented here clarify the link between various iron species with disease and 
provide a basis for optimal clinical trial design and outcome evaluation.  
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Caption for picture: 
Filings of elemental iron separated magnetically from a homogenate of breakfast cereal implicated in risk of 





Accessed September 20, 2017 
 
 



























































































































  Revised for re-submission: December 4, 2017 
Iron Reduction Response and Demographic Differences between Diabetics and Non-
Diabetics with Cardiovascular Disease Entered to a Controlled Clinical Trial  










 Veterans Affairs New England Health Care System, Research Service (151), VA 
Medical Center, 215 North Main Street, White River Jct., Vermont 05009, USA and the 
Department of Medicine, Geisel School of Medicine at Dartmouth College, Lebanon, 
New Hampshire, USA. E-mail: leo.r.zacharski@dartmouth.edu :  Tel: 802 295 9363  
b
 Veterans Affairs Cooperative Studies Program Coordinating Center, Veterans Affairs 
Palo Alto Health Care System, 3801 Miranda Road, Palo Alto, California 94304, USA.  
Email addresses: Bruce.Chow@va.gov, Galina.Shamayeva@va.gov; Phone: 650-493-
5000, ext 22536  
 
 
*Corresponding author: E-mail: leo.r.zacharski@dartmouth.edu  
Fax: 603-650-6786 











































































































































Iron-catalyzed oxygen free radical-induced oxidative stress mediates the pathogenesis of 
diabetes and cardiovascular disease (CVD). Diabetics (n=473) and non-diabetics (n=804) 
with CVD entered to a randomized trial of iron (ferritin) reduction by calibrated 
phlebotomy (www.clinicaltrials.gov, Identifier NCT00032357) had comparable iron 
measures at entry but diabetics had greater burden of CVD and comorbidities, lower 
hemoglobin and hematocrit levels, and higher glucose levels than non-diabetics. Entry 
iron measures were lower in diabetics on hypoglycemic therapy compared to diabetics 
untreated previously. Diabetics and non-diabetics had comparable iron measures during 
follow-up. Loess analysis of paired ferritin and hemoglobin, and paired ferritin and 
glucose levels in diabetics randomized to phlebotomy showed higher ferritin levels 
associated with lower hemoglobin and higher glucose levels. Progressive ferritin 
reduction in diabetics comported with rising hemoglobin and falling glucose levels 
neither of which reached levels observed in non-diabetics. We postulate that phlebotomy-
triggered autophagy (ferritinophagy) released redox-active iron sequestered 
intracellularly worsening anemia and glucose utilization that corrected partially with 
ferritin reduction. Intracellular redox-active iron levels contributory to disease, not 
reflected in peripheral iron measures, may persist because of glycation of iron transport 
proteins in diabetes. These findings suggest novel strategies for disease prevention and 








































































































































 An extensive basic and clinical literature on the contribution of iron in 
physiologic excess, particularly redox-active (non-transferrin-bound) iron (NTBI), to the 
pathogenesis of atherosclerotic cardiovascular disease (CVD) 
1-6
 and diabetes 
5-13
 has 
been reviewed. Epidemiologic and clinical studies have documented the impact of 
pathologic iron-catalyzed reactive oxygen species (ROS) on proteomic and metabollomic 
derangements in diabetes and atherosclerosis. Thus, both share pre-morbid excess dietary 
heme and non-heme iron as up-stream predisposing risk factors, 
1-6,14-21
 iron toxicity (risk 
and mortality) as a function of dose over time, 
21-23
 and greater frequency and severity of 
both in populations having relatively higher levels of body iron 
21-31
 while populations 
having lower iron status are relatively protected. 
21-23,32-34
 Both associate with co-
morbidities linked to aberrant iron homeostasis including malignancy, 
31,35-37
 diseases of 






 and smoking. 
43
  
 Studies of the contribution of iron to atherosclerosis have emphasized toxicity 
mediated by NTBI-catalyzed ROS effects on macrophages and endothelial cells, 
1-6,44-47
 
and lipid oxidation. 
48
 The conspicuously increased risk of CVD with diabetes 
12,13,31,49-55 
suggests that altered glucose homeostasis may support mechanisms that accelerate 
vascular disease expression. Thus, iron-driven oxidative stress contributes to pancreatic 
beta cell damage, 
56-59
 insulin resistance 
60-62
 and microvascular disease 
63-67
 in diabetes. 
Hyperglycemia alters hepcidin regulation of cellular iron uptake 
68-70
 and glycates critical 
macromolecules 
63-73
 resulting in reduced capacity of proteins of iron transport, including 
ferritin 
74
 and transferrin, 
75-80
 to detoxify NTBI. Ferritin levels in both diabetes and CVD 
predict risk of incipient disease above threshold levels of about 100 ng/mL. 
1-13,17,20-23
  
 Knowledge of threshold levels for iron toxicity plus the ability to lower ferritin 
levels to improve outcomes 
81-89
 suggest interventions that may ameliorate both. 
21,88-91
 
The Iron and Atherosclerosis Trial (FeAST); a 6-year, prospective, randomized, single-
blinded controlled clinical trial; was established to determine effects of iron (ferritin) 
reduction by calibrated (graded) phlebotomy to levels considered of minimal risk on 
clinical outcomes in peripheral arterial disease (PAD) representative of advanced CVD. 
91,92
 Data from this study analyzed according to randomization status failed to show an 
improvement in primary (all-cause mortality) or secondary (death plus non-fatal 



























































































































myocardial infarction or stroke) with randomization to iron reduction. 
91
 However, this 
paper also reported a sharp age-related improvement in primary (p=0.02) and secondary 
(p<0.001) outcomes with comparable measures of probability in entrants in the youngest 
age quartile. Improved outcomes were also reported in this paper with iron reduction in 
smokers for primary (p=0.06) and secondary (p<0.006) outcomes. 
91
 Benefits in smokers 
were subsequently confirmed. 
43
 An explanation for the interaction of clinical outcomes 
with age was forthcoming upon recognition that ferritin levels are a “natural” variable 
related for example to diet, iron supplement ingestion, blood testing, diabetes treatment 
(current paper), surgical bleeding, etc., in addition to their being the dependent 
experimental variable in this clinical trial. Importantly, lower ferritin levels select for 
increased longevity in the aging male population. 
21,32,93
 Thus, increasing age in subjects 
randomized to the control regimen associated with progressively lower entry ferritin 
levels 
32
 while participants randomized to iron reduction showed low entry ferritin levels 
in younger individuals that rose progressively with increasing age, an effect attributable 
to reduced compliance with phlebotomy with older age. 
32,91,93
 Thus, the ferritin level, the 
major study outcome variable, was more informative for displaying improved outcomes 
with lower body iron stores (ferritin levels) using Cox regression analysis in subsequent 
reports. 
93
 Further analyses showed lower ferritin levels indicative of reduced iron stores 
91-95
 and higher percent transferrin saturation (%TS) levels indicative of increased 
detoxification of iron and redox-active iron 
21,29
 associated with improved clinical 
outcomes. 
21,20,91,93,96
 Variables identified within the FeAST data set interacting with 
ferritin levels to influence outcomes included age, 
91,93
 smoking status, 
43






 The apparent lack of responsiveness to iron reduction in diabetics reported earlier 
from the FeAST study 
91
 was puzzling considering the overwhelming evidence for iron 
involvement in the pathogenesis of diabetes as referenced here and elsewhere. 
21
 Recent 
advances in our understanding of the metallomic basis for ferrotoxic disease 
20
 have 
facilitated data analyses capable of clarifying the explanation for varying effects of iron 
reduction according to pathophysiology unique to individual disease entities such as 
diabetes. Thus, FeAST data have demonstrated thresholds between physiologic ferritin 
(iron burden) and %TS (iron transport and sequestration) levels associated with reduced 



























































































































disease risk versus un-physiologic levels associated with increased disease risk. 
21
 The 
differential interpretation of ferritin versus %TS levels for gauging the extent and 
consequences of iron excess; 
21,23,29
 the effects of proteins of iron transport that are 
functionally impaired because of glycation; 
63-80,97
 and the differing relationships between 
hemoglobin (a surrogate for physiologic iron requirements), ferritin and %TS levels 
between diabetics and non-diabetics have been observed. 
21
 While not measured directly 
in FeAST, the critical contribution of excess NTBI in diabetes to more advanced macro-
vascular disease, 
49-54,67
 microvascular complications, 
44,63-66,72,73
 insulin resistance 
60-62,87-
89,98-100
 and the “anemia of chronic disease” including the anemia of diabetes 
101-111
 has 
been recognized increasingly. These abnormalities have been attributed to the ability of 
NTBI to penetrate cells and tissues. 
111-113
 Levels of NTBI correlate with higher levels of 
both serum ferritin and tissue iron in several conditions of iron overload. 
114-122
 NTBI 
levels may be responsive (at least partially) to iron mobilization by phlebotomy. 
123,124
 
Iron-catalyzed hydroxyl ion generation with heightened oxidative stress in diabetes 
125
 
has been shown to precipitate an insoluble gel of fibrin plus other proteins, termed 
“parafibrin”, that resists clot lysis 
126
 and is observable by scanning electron microscopy 
within the diabetic vasculature. 
127
 
 The purpose of this report is to describe demographic differences in CVD subjects 
with versus without diabetes entered to the FeAST trial, and to document divergent 
responses to iron reduction intervention between diabetics and non-diabetics. Such 
differences clarify the metallomic basis for disease capable of impacting clinical 
outcomes.  
 
Materials and Methods  
The FeAST study; a 6-year, prospective, randomized, controlled single-blinded 
clinical trial of iron reduction by graded phlebotomy (Trial Registration: 
www.clinicaltrials.gov, Identifier NCT00032357); 
91,92,96
 tested the hypothesis that 
improved clinical outcomes might be achieved in subjects with established PAD by 
reducing iron stores to levels typical of children and pre-menopausal women (about 25 to 
60 ng/mL). The Consort Diagram 
91
 and methodological details of study protocols; 
informed consent, randomization and intervention procedures; outcome assessment and 



























































































































study administration have been reported. 
91,92,96
 This study was carried out in accordance 
with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for 
experiments involving humans. Institutional Review Boards (IRBs) at each of the 24 
participating hospitals and a national IRB approved the protocol. Consenting (primarily 
male) patients over age 21 with stable PAD were computer randomized by age, ferritin 
level, HDL/LDL cholesterol ratio, diabetes and smoking status, and medical center. 
91,92
  
Racial categories were self-reported using standard federal guidelines 
128
 and were 
recorded here as either White or non-White (i.e., primarily Black). Smoking was recorded 
as ever versus never used inhaled tobacco products regularly. 
43,91,92
 “Current smokers" at 
the time of this study were those smoking regularly within one year. About 95% of 
participants used tobacco products regularly in the past, 
43,91
 while 42% of participants 
were smoking regularly at the time of the study (Table 1). Medication use was tracked 
prospectively at entry and during the study. Alcohol consumption was scored as either 
used or not used currently. Diabetes and hypertension were scored when the diagnosis 
was made clinically and required treatment. 
91,92 
Consistent with American Diabetes 
Association (ADA) guidelines, 
129
 no attempt was made to distinguish between type 1 
and type 2 diabetes in this population of older adults. Cardiovascular disease co-
morbidities (Table 2) scored on data sheets at entry were as follows: For atherosclerotic 
heart disease (ASHD): angina, myocardial infarction (MI), percutaneous procedure, 
coronary artery bypass surgery and treated dysrhythmia. For atherosclerotic 
cerebrovascular disease (ASCVD): carotid artery stenosis, stroke, transient ischemic 
attacks, stenting and endarterectomy. For PAD: reconstructive surgery, percutaneous 
procedure, amputation, endarterectomy, aneurysm resection, surgery for occlusive 
disease, rest pain and ischemic foot ulcers. 
92
  
Study design excluded individuals with an hematocrit (hct) of less than 35%, a 
ferritin greater than 400 ng/mL, a creatinine of 3.0 mg/dL or greater, abnormal liver 
enzyme levels, inflammatory conditions that may alter ferritin levels, a diagnosis of 
visceral malignancy within the past 5 years and disorders of iron metabolism including 
iron deficiency and hemochromatosis. 
91,92
  
Participants received standard of care disease treatment. For participants 
randomized to iron reduction, the entry ferritin level was used to calculate the amount of 



























































































































blood drawn to achieve the required decrement in serum ferritin [(initial ferritin – 25) X 
10 = mL of blood to be removed]. 
92,96
 No more than one unit (500 mL) of blood was 
drawn at the time of phlebotomy and sessions were no more frequent than weekly. 
Trough ferritin levels following phlebotomy were calculated to be about 25 ng/mL and 
peak levels measured prior to the next 6-monthly phlebotomy about 60 ng/mL, 
92,96
 levels 
postulated to be associated with improved outcomes. 
96-98,100
 Patients were followed at 6-
monthly intervals on an intent-to-treat basis regardless of performance of iron reduction, 
the amount of blood removed, or the rapidity or degree of ferritin reduction achieved.  
Follow-up ferritin levels reported are the 6-monthly measured (maximum) values 
used to re-calculate the amount of blood to be removed to achieve a trough ferritin 
decrement of 25 ng/mL at each 6-monthly interval. 
91,92,96
 Iron reduction was deferred if 
interval bleeding had occurred, the physician judged the procedure to be not in the 
patient’s interest, the patient declined, the hct was <35% or when the calculated amount 
of blood to be removed was less than 100 mL.  
Statistical Methods  
Statistical procedures, including Chi Square test or Wilcoxon tests used to 
compare baseline characteristics, and sample size calculation for this clinical trial have 
been described previously. 
91,92,96
 Compliance with phlebotomy was assessed in this 
report by the separation of ferritin values between the control and iron reduction 
interventions over time (Tables 4 and 5). Body mass index (BMI) was calculated as 
weight in kilograms divided by the height in meters squared, based on direct 
measurements. Results reported here are presented as the number (n) and percent, or the 
mean +/- standard deviation (SD) unless otherwise specified. The %TS was calculated by 
dividing the value for the serum iron level by the total iron binding capacity.  
 Loess Locally Weighted Scatter Smoothing Plot analysis 
130-133
 was used to detect 
interrelationships between ferritin reflecting iron burden, hemoglobin levels (a surrogate 
for physiologic iron status), and glucose levels reflecting glycemic control. This method 
permits construction of a smooth curve to visualize relationships between paired 
variables over a continuum not otherwise recognizable within large populations. 
130-133
 
Inflection points in the curves allow identification of sub-populations within the larger 
clinical trial population with graded changes based on direct laboratory measurements 



























































































































representing changing pathophysiologic status. The present study plots relationships 
between ferritin levels and levels of either hemoglobin or glucose sorted by 
randomization status (control or iron reduction plotted separately). The purpose was to 
explore effects of iron reduction, based on the dependent variable (the ferritin level), in 
relation to the hemoglobin level or glycemic control. Loess analysis was based on 3098 
samples with paired hemoglobin - ferritin levels in diabetics and 5289 samples with 
paired hemoglobin - ferritin levels in non-diabetics; and 2737 samples with paired ferritin 
- glucose levels in diabetics and 4629 samples with paired ferritin – glucose levels in 
non-diabetics. The range of values for ferritin, %TS, hemoglobin and glucose are shown 
on the figure axes.  
 
Results and Discussion 
 Crichton has summarized the essential role of catalytic iron in biological systems. 
134
 In brief, iron is required for metabolism of oxygen critical for energy production and 
for production of reactive oxygen intermediates involved in normal cell signaling. The 
contribution of catalytic iron to normal metabolism versus toxicity is highly 
concentration dependent and iron levels must be sufficient to meet energy demands but 
not above the capacity of proteins, such as ferritin and transferrin, to capture and detoxify 
potentially harmful NTBI. Reactive oxygen species (ROS), and particularly hydroxyl 
radical catalyzed by un-physiologic levels of NTBI, are highly damaging to critical bio-
molecules. In Crichton’s words: this understanding allows “the reader to more easily 
appreciate the diversity of biochemical functions which iron can play, viewed through the 
ligands which bind it to the protein.” Numerous basic, clinical and epidemiologic studies 
of the common iron binding proteins, ferritin and transferrin, allow assessment of iron 
balance required to sustain health and longevity, and to avoid risk of ferrotoxic diseases 
such as CVD and diabetes that are of particular interest in the current context. 
21 
 
 The FeAST study was open to patients with CVD regardless of comorbidities, 
race or sex. Few females were entered because participants reflected the clientele of the 
VA Hospital System. Entry criteria were pre-specified and randomization was balanced 
for potential outcome variables including ferritin levels and diabetes status. 
91,92,96
 This 
study entered 1,277 primarily male veterans with CVD having an average age of 67 at 



























































































































entry from 24 hospitals including 473 diabetics and 804 non-diabetics.  Table 1 shows 
that a similar proportion of participants with and without diabetes were male and ever 
smokers but a greater proportion of non-diabetics were current smokers (p<0.001). 
Diabetics and non-diabetics had similar homocysteine levels and HDL/LDL ratios. Age 
and fibrinogen levels trended higher in diabetics. Diabetics were less likely to be of 
White race (p=0.002) and to use alcohol (p<0.001). However, diabetics were more likely 
to be hypertensive and use statins, to have higher BMI and glucose levels, and lower 
hemoglobin and hematocrit values compared to non-diabetics (p<0.001 for each 
comparison). The distribution of demographic variables at entry in cohorts with and 




 Table 2 shows increased CVD burden in diabetics versus non-diabetics at entry, 
particularly for ASHD (p<0.001), for those with two (p=0.003) and three (p=0.051) CVD 
co-morbidities in addition to PAD (see Methods for definitions), and for amputation prior 
to study entry (p<0.001).  Table 3 shows comparable iron status at entry for participants 
with versus without diabetes.  
 Table 4 shows that randomization to iron reduction lowered body iron stores 
represented by ferritin levels comparably in those with and without diabetes (p<0.001 for 
both). The iron hypothesis appears to have been tested successfully in this clinical trial.
 91
  
Red cell values were lower at entry (Table 1) and during follow-up (Tables 4 and 5) in 
diabetics compared to non-diabetics. Table 4 also shows that hemoglobin and hematocrit 
values were improved (higher) (p<0.001) following phlebotomy in diabetics but 
remained at pre-phlebotomy (higher) levels following iron reduction in non-diabetics (see 
also Figure 1). Table 5 shows comparable iron measures during follow-up in diabetics 
and non-diabetics randomized to iron reduction by phlebotomy. Table 5 also shows that 
hemoglobin and hematocrit levels remained lower in diabetics randomized to both iron 
reduction and control groups although levels of red cell measures rose with iron reduction 
in diabetics (Tables 4 and 5, Figure 1). 
 Table 6 shows entry ferritin, %TS and glucose levels in diabetics treated with oral 
hypoglycemic drugs, insulin or both in comparison with neither treatment. Relationships 
between diabetes treatment and iron biomarker levels were examined because of 



























































































































evidence that metformin treatment is capable of lowering ferritin levels 
135
 possibly due 
to the metal-binding properties of this drug. 
136
 Those not receiving anti-diabetic 
treatment at entry were presumably newly diagnosed as having diabetes and eligible for 
study entry but not yet on treatment. Mean entry ferritin and %TS levels were lower in 
diabetics on oral hypoglycemic drugs, p=0.043 and p=0.045, respectively. Ferritin and 
%TS levels in those on insulin trended lower, p=0.056 and p=0.069, respectively. In 
contrast, glucose levels were higher in diabetics on treatment, likely related to the clinical 
indication for treatment with oral agents or insulin. In individuals on both treatments, 
glucose levels were higher (p<0.001) and %TS levels trended higher (p=0.073), while 
ferritin levels were higher than ferritin levels with individual treatments and not lower 
than ferritin levels in those on no treatment (p=0.424). Results in individuals requiring 
both oral therapy and insulin apparently represent more severe diabetes status. We note 
that effects of metformin on ferritin levels have been implicated in the favorable effects 
of this drug on other diseases considered to have a ferrotoxic basis. 
137-144
 
 Incentive for analyses shown as Loess curves in Figure 1 consisted of evidence 
that anemia of chronic disease, as exists in diabetics, 
45,145
 while considered commonly to 
be due to iron deficiency, is instead a state of iron overload with inflammatory 
impairment of iron utilization. 
146
 Construction of these Loess curves was further 
incentivized by finding increased hemoglobin values in diabetics randomized to iron 
reduction (Tables 4 and 5), an effect not seen in non-diabetics. This suggested that 
pathologic effects of iron excess in diabetics may differ qualitatively, for example, due to 
increased tissue NTBI, compared to effects in non-diabetics. Such effects of tissue NTBI 
might explain the lack of responsiveness to iron reduction in diabetics found previously. 
91
  
 Loess smoothing plots shown in Figure 1 represent paired hemoglobin and ferritin 
levels in diabetics and non-diabetics randomized to either iron reduction or control. 
Hemoglobin levels were consistently lower across the range of values in diabetics 
compared to non-diabetics. Overall hemoglobin levels were higher in subjects 
randomized to iron reduction in both diabetics and non-diabetics in the lower range of 
ferritin values but hemoglobin levels were lower in iron reduction patients in the higher 
range of ferritin levels. Reduction in hemoglobin levels with higher ferritin levels was 



























































































































more severe in diabetics compared to non-diabetics. The inflection point observed in non-
diabetics plateaued at ferritin levels of about 80 to 100 ng/mL indicating levels of iron 
(represented by ferritin levels) up to which increasing iron contributes to physiologic iron 
requirements represented here by increasing levels of hemoglobin. 
21
 The inflection point 
for diabetics randomized to the control group was similar to that of non-diabetics but at 
lower hemoglobin levels (Tables 1, 4, 5). A more abrupt inflection point was found for 
diabetics randomized to iron reduction at a lower ferritin level of about 50-60 ng/mL 
compared to control subjects. Curves representing iron reduction and control subjects 
crossed at a ferritin level of about 150 ng/mL in non-diabetics and about 200 ng/mL in 
diabetics (see vertical arrows).  
 Phlebotomy reduces iron stores (ferritin levels) by removal of red cells bearing 
hemoglobin iron. Restoration of pre-phlebotomy red cell levels occurs as iron drawn 
from the non-physiologic storage compartment is incorporated into newly formed red 
blood cells in bone marrow. The pattern in Figure 1 suggests that restoration of 
hemoglobin levels may be delayed following more intensive phlebotomy therapy at 
higher ferritin levels, a delay that is exaggerated in diabetics compared to non-diabetics. 
Delayed restoration of hemoglobin levels presumably reflects inhibition of erythropoiesis 
by increased levels of NTBI known to exist in diabetics. 
44,46,147
 The potential inhibitory 
effect of intracellular NTBI on erythropoiesis may be less than fully appreciated because 
of the relatively low peripheral blood ferritin and %TS levels. 
80,148,149
 NTBI penetrates 
cells and tissues including red cell precursors in bone marrow 
101-115
 where it inhibits 
erythropoiesis and reduces red cell survival. 
115
 Suppression of erythropoiesis due to 
release of NTBI would be expected to diminish as overall iron stores decline with 
continued iron reduction. As ferritin levels fell below about 200 ng/mL in diabetics and 
below about 150 in non-diabetics randomized to iron reduction (see vertical arrows in 
figure 1), the erythropoietic response appeared to increase the hemoglobin to levels 
higher than those present at higher ferritin levels and higher than hemoglobin levels in 
participants randomized to control. Hemoglobin levels in diabetics randomized to control 
remained relatively constant over the range of ferritin levels suggesting that tissue levels 
of NTBI may remain in stable association with intracellular proteins, especially ferritin, 




























































































































 unless interrupted by iron reduction intervention. To our knowledge, improvement of 
anemia of chronic disease with iron reduction has not been reported previously. 
 Incentive for construction of the Loess curves shown in Figure 2 consisted of 
evidence for a relationship between insulin resistance and increased iron, NTBI, in 
diabetics, 
60-62,97-99 
and evidence that iron reduction was capable of reducing glucose 
levels in diabetics. 
87-89 
These Loess smoothing plots show paired glucose and ferritin 
levels in diabetic and non-diabetic cohorts randomized to either the control or iron 
reduction regimens. As expected, glucose levels were higher in diabetics. Mean glucose 
levels in non-diabetics (about 100 mg/dL) and diabetics randomized to control (about 150 
mg/dL) were similar to levels reported for the overall diabetic and non-diabetic cohorts at 
entry (Table 1). The relationship between ferritin and glucose levels in non-diabetics or 
diabetics randomized to the control regimen, and in non-diabetics randomized to iron 
reduction remained unchanged over the range of ferritin values. In contrast, diabetics 
randomized to iron reduction showed maximum glucose levels in excess of about 200 
mg/dL associated with the highest ferritin levels with gradually declining glucose levels 
associated with decreasing ferritin levels to reach a minimum of about 150 gm/dL at 
ferritin levels of about 50 ng/mL (see vertical arrow). Higher glucose levels in diabetics 
below ferritin levels of about 50 ng/mL reflect presumably basal insulin resistance in this 
diabetic cohort. As in Figure 1, data in Figure 2 suggest that tissue levels of NTBI in 
stable association with ferritin contribute to mechanisms of insulin resistance in diabetics 
that becomes exaggerated when interrupted by iron reduction intervention.   
 Direct measures of NTBI, hepcidin, insulin resistance and protein glycation were 
not available in FeAST. The range of values shown on the axes of figures 1 and 2 were 
limited by protocol entry requirements and do not necessarily represent the full range of 
values that might be observed clinically. However, effects of iron reduction shown in 
Figures 1 and 2 are consistent with the concept that mobilization of iron may release a 
transient deluge of NTBI that is more pronounced quantitatively at higher ferritin levels. 
Such release of NTBI has been described with surgical stress 
151
 and tissue injury 
152
 that 
may be augmented by relief of hepcidin-inhibited tissue iron release as iron stores 
decline. 
153
 Noxious NTBI sequestered intracellularly capable of inhibiting erythropoiesis 
may explain why “anemia” associates with mortality in hospitalized patients. 
118
 Studies 



























































































































linking acute changes in iron species in diabetics to autophagy, 
154,155
 insulin receptor 
function 
156-158
 and NTBI release 
159,160
 support this interpretation. Exaggerated insulin 
resistance with phlebotomy in diabetics suggests a mechanism for precarious glycemic 
control with surgery when accompanied by blood loss.
161  
 
Danielpur et al., 
159
 studied insulinoma cells characterized by reduced insulin 
expression with increased iron content and ROS expression. Treatment of the cells with 
an iron chelator reduced intracellular iron and ROS, and increased insulin secretion. 
These improvements in vitro were augmented upon treatment with a glucagon-like 
peptide-1 receptor antagonist (GLP-1-RA). Similar effects of GLP-1-RA treatment were 
observed clinically suggesting that clinical benefits achieved with GLP-1-RA treatment 
of diabetes may be improved further if combined with iron reduction by chelation. GLP-1 
has anti-oxidant properties and GLP-1-RA renders GLP-1 more resistant to degradation 
which may account for beneficial effects of GLP-1-RA treatment of diabetes. 
162
 Our data 
reinforce the concept that NTBI contributes to oxidative stress in diabetes and commend 
trials of iron reduction by phlebotomy rather than pharmacologic chelation for this 
purpose.
 
 Sahni et al. 
160
 summarized evidence for concentration-dependent effects of iron 
on autophagy, a homeostatic catabolic pathway for intracellular breakdown of proteins 
and organelles. 
163
 Autophagy-related ferritin degradation (ferritinophagy) is the 
physiologic mechanism that reduces intracellular ferritin levels observed subsequently as 
reduced peripheral ferritin levels in response to iron depletion. Under conditions of 
persistently higher intracellular iron concentrations, intracellular ferritin is stabilized with 
iron complexation. 
150
 However, under conditions of falling body iron stores, 
ferritinophagy increases. In the absence of iron excess, this mechanism serves to regulate 
intracellular ferritin levels commensurate with physiologic iron homeostasis. 
150,160
 With 
extreme iron excess, exaggerated autophagy may contribute to cell death (ferroptosis) 
triggered by NTBI-initiated ROS production 
164,165
 resulting in lysosomal membrane 
permiabilization and cellular demise. 
160
 Regulation of this pathway by iron chelation 
160,164
 suggests that similar benefits may be achieved by re-partitioning iron non-
pharmacologically from tissues into the red cell compartments by phlebotomy. 
Temporarily increased inhibition of red cell production shown in Figure 1 and increased 



























































































































glucose levels (temporarily increased insulin resistance) shown in Figure 2 exemplify 
such responses to phlebotomy.   
Conclusions 
 Ferritin and %TS levels for diabetics and non-diabetics were comparable at entry 
and follow-up (Tables 1,3-5) suggesting that this test of the iron hypothesis was 
successful. 
91
 Uniform entry and pre-defined intent-to-treat follow-up and data collection 
procedures together with its longitudinal design and virtually complete follow-up in 
diabetics and non-diabetics lend validity to comparisons at study conclusion. Comparison 
of demographics and serial responses of iron biomarkers to phlebotomy illustrate 
differential biological effects of the metallome between primarily male diabetic versus 
non-diabetic cohorts with CVD. However, data from participants in study cohorts as 
defined may not represent the range of values in the general population. This study 
included primarily male participants and similar data on females were not available.  
 At entry, diabetics had greater burden of CVD and comorbidities (Table 2), lower 
hemoglobin and hematocrit levels and higher glucose levels compared to non-diabetics 
(Tables 1,3-5; Figures 1 and 2). These characteristics of diabetes may result from 
increased tissue NTBI levels not measured reliably by peripheral iron biomarker levels. 
Patterns of interactions between ferritin and hemoglobin levels, and between ferritin and 
glucose levels observed on Loess analysis of paired values according to randomization 
status may be explained by induction of autophagy (ferritinophagy) in participants 
randomized to iron reduction thus disclosing release of a burst of NTBI within tissues. 
The result appeared to be temporary augmentation of suppression of erythropoiesis 
(Figure 1) and insulin resistance (Figure 2). Progressive ferritin reduction resulted in 
continuously rising hemoglobin and declining glucose levels in diabetics that appeared 
optimal at ferritin levels below about 50 to 60 ng/mL, although failing to reach levels in 
non-diabetics (Figures 1 and 2). This failure is likely due to persistent malfunction of 
proteins of iron transport due to glycation in diabetics 
73-80
 despite achievement of low 
peripheral levels of ferritin comparable to those observed in non-diabetics. The existence 
of residual NTBI at relatively low ferritin levels, represented indirectly by lower 
hemoglobin and higher glucose levels, might correspond to NTBI-mediated mechanisms 
for the increased risk of CVD and micro-vascular co-morbidities despite similar 



























































































































peripheral measures of iron status in diabetics and non-diabetics at entry and during 
follow-up (Tables 1-5). 
91
 Thus, interpretation of effects of iron status on clinical 
outcomes should consider not only the differential interpretation of peripheral ferritin and 
%TS levels, 
21
 but also the contribution of tissue NTBI to ferrotoxic disease. 
20,166
 
Methodologies for measuring NTBI peripherally are technically difficult 
167
 and NTBI 
may be bound to numerous proteins with variable capacity for detoxification. 
72-75
 Tissue 
NTBI that eludes conventional assay methodologies may be observed indirectly as 
illustrated in Figures 1 and 2. The strength of these observations may rest in the 
observation of transition over time from high (at risk) to low (more physiologic) ferritin 
levels that corresponded to serial changes in intermediate hemoglobin and glucose levels. 
Graded transitions in laboratory values observed on Loess analysis based on “live” 
patient samples show break points and trends in curves that lend themselves to 
interpretation as clinically realistic transitions between physiologic and pathologic levels 
of iron. These unprecedented findings may define differences in response to ferritin 
reduction by phlebotomy between diabetics and non-diabetics that may contribute to 
differences in clinical outcome.  
 Anemia of chronic disease is commonly unresponsive to oral iron and may 
require high dose parenteral iron for correction. 
146
 Such anemia having elevated tissue 
iron and ferritin levels but lower serum iron and %TS levels may be explained by levels 
of hepcidin that are inappropriately high for the degree of anemia. 
146
 Our findings 
(Figure 1) suggest that the anemia of chronic disease may be treatable by phlebotomy 
iron reduction capable of relieving systemic and intracellular iron burden while restoring 
physiologic hepcidin function. Correction of anemia of chronic disease by iron reduction 
may be more effective in conditions other than diabetes in which protein glycation is not 
a factor. The value of non-pharmacologic iron reduction 
168
 for management of insulin 
resistance has received little attention. 
169
  
 Results reported here affirm the considerable evidence for adverse effects of iron 
overload in human disease susceptible to management by avoiding excessive dietary iron 
intake or iron reduction therapy. 
14-16,19-23
 Future studies in diabetics might consider 
combining iron reduction intervention with treatment to reduce levels of glycated 
proteins more effectively. 
74-80,159
 Clarification of mechanisms will require incorporation 



























































































































of measures of hepcidin, NTBI and glycated protein levels as well as measures of 
peripheral and cellular iron status.  
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Table 1: Comparison of demographic and laboratory variables between diabetics and non-
diabetics at entry (see text for details). 
   Diabetic  Non-diabetic 
Variable   (n =  473)    (n = 804)  p-value 
Age    68 ± 8    67 ± 9    0.070 
Male (n,%)   470 (99.37%)   792 (98.51%)   0.281 
White race (n,%) 379 (80.13%)   697 (86.69%)   0.002 
Ever smoked   448 (94.71%)   775 (96.39%)   0.153 
Current smoker 160 (33.83%)  384 (47.76%)           <0.001 
Alcohol use   95 (20.08%)   281 (34.95%)            <0.001 
Statin use   309 (65.33%)   448 (55.72%)   0.001 
Hypertension   392 (82.88%)   585 (72.76%)            <0.001 
Body mass index  29.5 ± 5   27.4 ± 4.9            <0.001 
Glucose (mg/dL) 159.2 ± 59.1   105.2 ± 20.7            <0.001 
Hematocrit (%)  42.9 ± 3.9   43.9 ± 3.8            <0.001 
Hemoglobin (g/dL)  14.5 ± 1.4   14.8 ± 1.4            <0.001 
HDL/LDL ratio  0.43 ± 0.19   0.44 ± 0.27   0.884 
Fibrinogen (mg/dL) 399 ± 98.1   386 ± 90   0.067 






































































































































Table 2: Comparison of vascular disease burden in addition to PAD in diabetics versus 
non-diabetics at entry: atherosclerotic heart disease (ASHD), cerebrovascular disease 
(ASCVD) and PAD plus vascular co-morbidities as defined in the text. 
    Diabetic  Non-diabetic 
Variable    (n = 473)   (n =  804)  p-value 
Any ASHD only   294 (62.2%)   407 (50.6%)            <0.001 
 
Any ASCVD only   186 (39.3%)   281 (35%)   0.118 
 
PAD as only vascular  231 (48.8%)   390 (48.5%)   0.954 
 manifestation 
One co-morbidity   385 (81.4%)   628 (78.1%)   0.174 
 
Two co-morbidities   243 (51.4%)   342 (42.5%)   0.003 
 
Three co-morbidities   83 (17.5%)   108 (13.4%)   0.051 
 






































































































































Table 3: Comparison of iron status (ng/mL, mean +/-SD or mean percent transferrin 
saturation, %TS) between diabetics versus non-diabetics at entry.  
    Diabetic  Non-diabetic 
Variable    (n =  473)   (n = 804)  p-value 
Determinants of Iron status 
Prior ingestion of   1.84+/- 0.37   1.82+/- 0.38   0.402 
 Iron supplements (%) 
Serum Iron (ng/ml)   79.5+/- 32.3   81.5+/- 29.8   0.145  
Total iron bindings            323.5+/- 56.6           322.2+/- 56.8  0.921 
 capacity (ng/ml) 
% TS     40.6+/- 30.2   39.7+/- 29.6   0.704  












































































































































Table 4: Comparison of iron status during follow-up in diabetics versus non-diabetics 
randomized to control versus iron reduction. The means of 6-monthly determinations are 
identified by the number (n); percent (%); overall MFFL = mean follow-up ferritin level 
(ng/mL, mean +/-SD); overall mean percent transferrin saturation (%TS); mean 
hemoglobin (g/dL); and mean hematocrit (%).  
     Control  Iron reduction 
Variable     (n)               (n )  p-value  
Diabetic (n)    235    238 
     MFFL (ng/mL)   114.6+/- 76   75.4+/- 55.6  <.001 
     n (%) with MFFL <75 ng/mL 8 (34.5%)   138 (58%)  <.001 
     n with >50% compliance     152 
     MFFL with >50% compliance    57.7 ± 27.3 
 (mean +/-SD) 
     Mean %TS    40.2+/-31.2  40.9+/-29.3   0.499 
     Mean follow-up hematocrit (%)  41.0+/-4.2   41.5+/-4.3  <0.001  
     Mean follow-up hemoglobin 13.8+/-1.4   13.9+/-1.5  <0.001  
 (g/dL) 
Non-diabetic (n)   406    398    
     MFFL (ng/mL)   127.2+/- 93.1   82.2+/- 80  <.001 
     n (%) with MFFL <75 ng/mL 117 (28.8%)   224 (56.3%)  <.001 
     n with >50% compliance     260  
     MFFL with >50% compliance    58.7 ± 33.8 
 (mean +/-SD) 
     Mean %TS    41.1+/-31.4  38.3+/-27.6 0.338 
     Mean follow-up Hematocrit (%)  43.0+/-3.8   43.0+/-3.9  0.337 
































































































































Table 5: Comparative effects of phlebotomy intervention on extent of iron reduction in 
diabetics and non-diabetics: 6-monthly MFFL = mean follow-up ferritin level; ng/mL, 
mean +/-SD; mean 6-monthly percent transferrin saturation, %TS; or number (N,n), %, 
and mean 6-monthly hematocrit (%) and hemoglobin (g/dL).  
     Diabetic     Non-diabetic p-value 
Randomization to iron reduction: (n=238)      (n=398)    
MFFL (ng/mL)    75.4 ± 55.6      82.2 ± 80  0.786 
N (%) with MFFL <75 ng/mL  138 (58%)     224 (56.3%) 0.675 
N with MFFL >50% compliance  (n= 152)      (n=260) 
 (mean +/-SD)   57.7 ± 27.3     58.7 ± 33.8  0.682  
Mean follow-up %TS   24.4 ± 21     26.6 ± 29.8   0.881 
Mean follow-up total iron   340.9 ± 53.4     339 ± 49.5  0.484 
 binding capacity (ng/mL) 
Mean follow-up Hematocrit (%)  41.5 ± 4.3      43.0 ± 3.9            <0.001 
Mean follow-up Hemoglobin  13.9 ± 1.5      14.5 ± 1.3            <0.001 
 (g/dL) 
 
Randomization to control:  (n=235)  (n=406) 
Mean follow-up Hematocrit (%)  41.0 ±4.2           43 ± 3.8           <0.001 






































































































































Table 6: Comparison of mean (SD) ferritin (ng/mL), percent transferrin saturation (%TS) 
and glucose (mg/dL) levels between diabetics on oral hypoglycemic drugs, insulin, both 
or neither at entry. The variable “n” refers to the slight variations in the numbers of cases 
on a given treatment having a corresponding ferritin, %TS or glucose value available for 
comparison with the “neither” treatment group. The p-value refers to the comparison with 
the “neither” treatment group.  
       Oral  
             Hypoglycemic            Insulin               Both                  Neither 
n     244-247           127-128              51-52                 42-43 
Ferritin          118.7 (80.4)           119.2 (83.7)      135.5 (93.2)        154.1 (102.0)  
  p=0.043        p=0.056         p=0.423 
 
%TS  24.9 (10)        24.7 (9.3)         25.3 (11.8)  27.8 (10.5) 
  p= 0.045        p=0.069          p=0.073  
 
Glucose         155.7 (40.9)         166.8 (75.3)      177.7 (63.2)  138.4 (35.2) 










































































































































Figure Captions:  
Figure 1. Loess smoothing plots of 3098 paired hemoglobin and ferritin samples in 
diabetics and 5289 paired hemoglobin and ferritin samples in non-diabetics sorted by 
randomization to iron reduction versus control regimens. The range of values is shown on 
the figure axes. An inflection point corresponding to maximum physiologic iron 
requirement (represented by the ferritin levels) for hemoglobin synthesis occurred at 
about 80 ng/mL in non-diabetics and diabetics randomized to the control regimen, and at 
about 60 ng/mL in diabetics randomized to iron reduction. Vertical arrows mark 
transition points from reduced to increased hemoglobin levels with randomization to iron 
reduction that occurred at ferritin levels of about 200 ng/mL in diabetics and about 150 
ng/mL in non-diabetics (see text for discussion and interpretation). 
 
Figure 2. Loess smoothing plots of 2737 paired glucose and ferritin samples in diabetics 
and 4629 paired glucose and ferritin samples in non-diabetics sorted by randomization to 
iron reduction versus control regimens. The range of values is shown on the figure axes. 
Higher glucose levels in proportion to the degree of ferritin elevation are observed in 
diabetics randomized to iron reduction that were not seen in diabetics randomized to 
control or in non-diabetics (see text for discussion and interpretation).  
 
 







































































































































































































































































Page 45 of 45 Metallomics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
M
et
al
lo
m
ic
s
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
is
he
d 
on
 1
1 
D
ec
em
be
r 
20
17
. D
ow
nl
oa
de
d 
by
 R
SC
 I
nt
er
na
l o
n 
12
/1
2/
20
17
 1
0:
08
:4
3.
 
View Article Online
DOI: 10.1039/C7MT00282C
